It has been shown that: 1) Cerdulatinib inhibits BCR-induced signaling; 2) Cerdulatinib inhibits chemokine secretion in response to BCR ligation and co-culture with nurse-like cells; 3) IL-4 mediated signalling and increased IgM expression are inhibited by cerdulatinib; 4) Cerdulatinib reduces CLL cell viability in a concentration, time and caspase dependent manner; 5) Cerdulatinib reduces cell viability in the presence of microenvironmental support and 6) Cerdulatinib and venetoclax synergize to induces substantial apoptosis in the presence of IL- 4/CD40L. Here, BCR is linked to B-cell chronic lymphocytic leukemia.